ZM-447439 is a potent and selective inhibitor of Aurora B kinase (IC50=50nM), Aurora A and C are inhibited at higher concentrations (IC50=1000nM and 250nM respectively). Other kinases such as Cdk1 and PLK1 are not inhibited (up to 10mM). Cells treated with ZM-447439 progress through interphase, enter mitosis and assemble bipolar spindles but chromosome alignment, segregation and cytokinesis all fail.
Product Details
| Formula: | C29H31N5O4 |
| |
| MW: | 513.6 |
| |
| CAS: | 331771-20-1 |
| |
| Purity: | ≥98% (TLC) |
| |
| Solubility: | Soluble in DMSO (25 mg/ml). |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | Ambient |
| |
| Use/Stability: | Store solutions at -20°C for up to 3 months. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Complete microtubule-kinetochore occupancy favours the segregation of merotelic attachments: D. Dudka, et al.; Nat. Commun.
9, 2042 (2018),
Abstract;
Full Text
Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts: E. Walsby, et al.; Haematologica
93, 662 (2008),
Abstract;
ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture: Z.J. Long, et al.; Cell Cycle
7, 1473 (2008),
Abstract;
Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores: C. Ditchfield, et al.; J. Cell Biol.
161, 267 (2003),
Abstract;
